On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened higher 3.60% from the last session, before settling in for the closing price of $11.53. Price fluctuations for NTLA have ranged from $5.90 to $28.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.04%. Company’s average yearly earnings per share was noted 20.79% at the time writing. With a float of $97.42 million, this company’s outstanding shares have now reached $103.54 million.
Let’s determine the extent of company efficiency that accounts for 403 employees. In terms of profitability, gross margin is 88.67%, operating margin of -1187.36%, and the pretax margin is -1154.1%.
Intellia Therapeutics Inc (NTLA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.95%, while institutional ownership is 92.22%. The most recent insider transaction that took place on Jul 01 ’25, was worth 10,036. In this transaction EVP, Chief Technical Officer of this company sold 1,022 shares at a rate of $9.82, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Jul 02 ’25, when Company’s VP, Chief Accounting Officer sold 2,503 for $9.95, making the entire transaction worth $24,905. This insider now owns 57,137 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 20.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.65% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 4.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.23, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.84 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Looking closely at Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days average volume was 4.86 million, which is a jump from its year-to-date volume of 3.96 million. As of the previous 9 days, the stock’s Stochastic %D was 86.36%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 87.18%, which indicates a significant decrease from 88.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.70 in the past 14 days, which was higher than the 0.70 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.06, while its 200-day Moving Average is $11.59. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $12.26. Second resistance stands at $12.57. The third major resistance level sits at $13.02. If the price goes on to break the first support level at $11.50, it is likely to go to the next support level at $11.05. Should the price break the second support level, the third support level stands at $10.74.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 103,583K shares outstanding in the company with a market cap of 1.24 billion. Presently, the company’s annual sales total 57,880 K according to its annual income of -519,020 K. Last quarter, the company’s sales amounted to 16,630 K and its income totaled -114,330 K.
